Janus Henderson Investors US’s Ligand Pharmaceuticals LGND Stock Holding History

Janus Henderson Investors US’s Portfolio LGND Stock Details LGND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	$28.7M	Sell	434,083 -1,885	-0.4%	-$124K	0.02%	545
2016 Q4	$27.6M	Buy	435,968 +103,051	+31%	+$6.5M	0.02%	559
2016 Q3	$21.2M	Sell	332,917 -60	-0%	-$4.41K	0.02%	578
2016 Q2	$24.8M	Buy	332,977 +4,689	+1%	+$348K	0.02%	538
2016 Q1	$21.9M	Sell	328,288 -3,876	-1%	-$236K	0.02%	569
2015 Q4	$22.5M	Sell	332,164 -47,808	-13%	-$2.95M	0.02%	584
2015 Q3	$20.3M	Buy	379,972 +58,958	+18%	+$3.58M	0.02%	606
2015 Q2	$20.2M	Buy	321,014 +197,423	+160%	+$10.8M	0.02%	602
2015 Q1	$5.95M	Buy	+123,591	New	+$4.74M	﹤0.01%	769

Other funds holding LGND

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

SCM

Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return

DMK

David M. Knott $275M AUM 59.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

CCMLC

Cardinal Capital Management LLC (Connecticut) Greenwich, Connecticut $365M AUM 18.32% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Janus Henderson Investors US's LGND Position: Q1 2017 in Review

Janus Henderson Investors US reduced its Ligand Pharmaceuticals (LGND) stake by 0.43% in Q1 2017, selling an estimated $124K and leaving 434,083 shares worth $28.7M. The position accounts for 0.02% of the portfolio, ranked #545.

Janus Henderson Investors US first reported a position in LGND in Q1 2015 and has held it in 9 quarters since. 257 funds tracked by Wall St. Rank hold LGND as of Q1 2017.

Janus Henderson Investors US held 434,083 shares of Ligand Pharmaceuticals worth $28.7M as of Q1 2017.
Janus Henderson Investors US sold 1,885 Ligand Pharmaceuticals shares in Q1 2017, an estimated $124K.
Ligand Pharmaceuticals made up 0.02% of Janus Henderson Investors US's portfolio in Q1 2017, its #545 holding.
Janus Henderson Investors US first reported a position in Ligand Pharmaceuticals in Q1 2015 and has held it in 9 quarters since.
257 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q1 2017.

Based on Janus Henderson Investors US's 13F filing for Q1 2017, filed 16 May 2017.